|
|
MPL-SE vaccine adjuvant |
|
Vaxjo ID |
104 |
|
Vaccine Adjuvant Name |
MPL-SE vaccine adjuvant |
|
Adjuvant VO ID |
VO_0001345
|
|
Stage of Development |
Clinical Trial |
|
Components |
monophosphoryl lipid A (MPL) plus squalene |
|
Function |
MPL, a naturally derived disaccharide of Salmonella minnesota, monophosphoryl lipid A plus squalene (MPL–SE) is an effective substitute for IL-12 (Skeiky et al., 2002). |
| Related Vaccine(s) |
|
| References |
Skeiky et al., 2002: Skeiky YA, Coler RN, Brannon M, Stromberg E, Greeson K, Crane RT, Webb JR, Campos-Neto A, Reed SG. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine. 2002; 20(27-28); 3292-3303. [PubMed: 12213399].
|
|
